Clinical Steering Group

“A study such as this will enable us to enhance our knowledge and understanding of parent decision-making processes in complex situations, and in doing so will enable the development of an intervention parents can use to support them in their treatment decision-making”
Healthcare Professional

Clinical Steering Group

Healthcare professionals will be involved with REDMAPP through:

  • Identifying potential participants who may take part in phase 1 of the study
  • Stakeholder workshops to support intervention development
  • Testing the intervention developed

To support the engagement of healthcare professionals, 3 recognised experts in neuroblastoma have been consulted in the development of REDMAPP:

Professor Andy Pearson is formerly a Cancer Research UK Professor of Paediatric Oncology, at the Institute of Cancer Research and the Royal Marsden Hospital NHS Foundation Trust. Professor Pearson authored the first international guidelines for the conduct of Phase I trials in children with cancer, and led the first paediatric Phase I study in the UK. He was the founding chair of International Society for Paediatric Oncology Europe Neuroblastoma Committee (SIOPEN), founding Co-Chair of the International Neuroblastoma Risk Group Strategy (INRG) and the Chief Investigator of the BEACON Trial; the first ever randomised European study for children with refractory/relapsed neuroblastoma.

He has held many international positions; including President of Advances in Neuroblastoma Research Association, Executive and Clinical Trial Committee of the Innovative Therapy for Children with Cancer Consortium (ITCC), Board membership of SIOPEN, and membership of the Steering Committee and chair of the Paediatric Strategy Forum Oversight Committee of the multi-stakeholder Paediatric Oncology Platform (ACCELERATE). He has published over 360 scientific manuscripts. 

He retired from clinical practice in May 2014 due to ill health. Professor Pearson was awarded a Lifetime Achievement Award from Advances in Neuroblastoma Research Association in 2016. 

Professor Pearson is chair of Solving Kids’ Cancer Scientific Advisory Board and Patron of Neuroblastoma UK.

Dr Juliet Gray is an Associate Professor in Paediatric Oncology at the Cancer Immunology Centre, University of Southampton. She leads a translational research group focused on novel antibody immunotherapies for neuroblastoma, including preclinical evaluation of novel combinational therapies as well as early-phase clinical trials.

Dr Gray’s specific research interests are in targeting anti-GD2 monoclonal antibodies, and immunomodulatory antibodies such as those targeting PD-1. She has developed the laboratory support and immune endpoint assays within the Southampton Experimental Cancer Medicine Centre, required to support early phase immunotherapy studies. 

Dr Gray was the UK Chief Investigator and member of the Trial Steering Committee for the SIOPEN Long Term Infusion of ch14.18 (anti-GD2) monoclonal antibody in children with relapsed/refractory neuroblastoma and is the Chief Investigator of the first-ever transatlantic neuroblastoma study to open in the UK, MiNivAn – a multi-centre Phase I trial combining targeted radiation therapy and two immune therapies (131-I MIBG, Nivolumab and ch14.18/CHO) for the treatment of children with relapsed or refractory neuroblastoma.

Dr Gray plays a key role in both UK and European neuroblastoma research. She is a member of the UK National Cancer Research Institute Children’s Cancer Group and Leukaemia Clinical Studies Group (NCRI CCL CSG) and neuroblastoma subgroup, Executive Member of the European Neuroblastoma Research Network (SIOPEN), and member of the SIOPEN Immunotherapy Committee.

Dr Lucas Moreno is a paediatric oncologist dedicated to early phase clinical trials and neuroblastoma. He trained in La Fe Hospital (Valencia, Spain), and started his career in the Royal Marsden Hospital (London, UK) back in 2008, under the mentorship of Prof Andy Pearson.

In April 2013, he created the Clinical Research Unit for Paediatric Phase I/II Trials at Hospital Niño Jesús in Madrid, Spain, a centre that is part of the Innovative Therapies for Children with Cancer (ITCC) European consortium, and focuses on the design and development of first-in-child phase I trials and early clinical trials of molecularly targeted agents and immunotherapeutics. Dr Moreno was recently appointed Clinical Director of Paediatric Oncology and Haematology at Vall d’Hebron Barcelona Hospital Campus.

Dr Moreno is the international Chief Investigator of the randomised phase 2 trial BEACON-Neuroblastoma open in 10 European countries for refractory/relapsed neuroblastoma, and has participated in the development of more than 30 early phase clinical trials for paediatric cancers. He has led the development of pharmacodynamic biomarkers for PI3K inhibitors in neuroblastoma which are now ready to be implemented in early clinical trials.

Dr Moreno chairs the Drug Development Group and is a member of the Executive Committee of the European Neuroblastoma Network (SIOPEN), and is a member of the Clinical Trials Committee of the ITCC consortium.